COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

Cancer-Associated Thrombosis: Defining, Risk Assessment, and Prognos…

BMFcases

T. Bat, M. Carrier

VTE Prophylaxis After THA in the Asians: Messages from 2019 AP VTE C…

Arthroplasty Society in Asia

A. Tanavalee

VTE Prophylaxis After THA: Chinese Experience

Arthroplasty Society in Asia

H. Cai

VTE Prophylaxis After THA for Asian Population: Pharmacological Prop…

Arthroplasty Society in Asia

M. Mihara

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Acute DVT: When to and When Not to Intervene?

Venous Edge

S. Elias, C. Pena, C. Huff, R. Winokur, K. BROWN

Medical Management of DVT

NY Endovascular Summit

J. Goldfinger

Extended Anticoagulation for VTE

Jeffrey Weitz

Prevention and Treatment of Cancer-Associated Thrombosis: What Are t…

James Douketis

Management of Acute Pulmonary Embolism: How Long Do You Treat?

NYU Langone

N. Amoroso

Thrombus Extending into the IVC

Venous Symposium

P. Muck

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for …

Keck School of Medicine of USC

L. Clavijo

Duration of Anticoagulation: Provoked vs Unprovoked VTE

PERT Consortium 2022

G. Barnes

Catheter Wars: The Thrombus Strikes Back

AVA 2022 Annual Scientific Meeting

A. Bulmer, P. Carr

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

Jerry Spivak